Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00574379 | Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR | PHASE2 | COMPLETED | 805 | — | — | Dec 1, 2007 | Mar 1, 2008 | Feb 15, 2019 | 13 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bilastine 20mg once per day |
| 2 | EXPERIMENTAL | Bilastine 20mg twice per day |
| 3 | EXPERIMENTAL | Bilastine 10mg once per day |
| 4 | EXPERIMENTAL | Bilastine 10mg twice per day |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bilastine | DRUG | Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets |
| Placebo | DRUG | Placebo tablets twice daily for 14 days |
Inclusion Criteria: * clinical history of Seasonal Allergic Rhinoconjunctivitis with seasonal onset and offset of nasal allergy symptoms * documentation of a positive skin test within one year of screening to Mountain Cedar allergen Exclusion Criteria: * significant medical condition * significan...